Biobot Closes $24M in Series B Funding


Biobot, a Singapore-based company which specializes in robotic prostate biopsy and treatment solutions, raised $24M in Series B funding.

The round was led by Mr. Tony Tan, with participation from ZIG Ventures, and the new strategic investors.

The company intends to use the funds to expand its presence worldwide and further develop its digital surgery infrastructure. 

Biobot is dedicated to redefining the standard of care in urology through technological innovation. Its flagship product, the iSR’obot Mona Lisa system, provides urologists with robotic precision and enhanced visualization for percutaneous transperineal procedures.

The technology is already being used globally more than 50 Mona Lisa robots deployed, and over 20,000 procedures completed.